SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Hospice and Palliative Medicine®
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wilson, G. R.
Right arrow Articles by Reisfield, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, G. R.
Right arrow Articles by Reisfield, G. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Morphine hyperalgesia: A case report

George R. Wilson, MD

Department of Community Health and Family Medicine, University of Florida Health Science Center, Jacksonville, Florida, Charles M. Neviaser Educational Institute, Community Hospice Northeast Florida, Jacksonville, Florida

Gary M. Reisfield, MD

Division of Palliative Medicine, Department of Community Health and Family Medicine, University of Florida Health Science Center, Jacksonville, Florida

We report a case of a patient with metastatic testicular cancer and intractable pain refractory to massive doses of oral, intravenous, and intrathecal (IT) opioids supported by analgesic adjuvants. During our efforts to control his pain, the patient exhibited opioid-induced hyperalgesia, an uncommon but important phenomenon seen with high-dose opioid therapy. With appropriate opioid adjustment—in this case reduction of intrathecal morphine dosage by a factor of 100—the condition rapidly resolved and the patient became pain-free and remained so until his death six weeks later. The keys to identifying this uncommon, but treatable, opioid side effect are recognizing it as a possibility when aggressive efforts to control pain with high doses of opioids, especially when administered neuraxially, are met with increasing pain.

Key Words: cancer • analgesia • hyperalgesia • pain opioid

American Journal of Hospice and Palliative Medicine®, Vol. 20, No. 6, 459-461 (2003)
DOI: 10.1177/104990910302000608


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Anesth. Analg.Home page
A. Singla, M. P. Stojanovic, L. Chen, and J. Mao
A Differential Diagnosis of Hyperalgesia, Toxicity, and Withdrawal from Intrathecal Morphine Infusion
Anesth. Analg., December 1, 2007; 105(6): 1816 - 1819.
[Abstract] [Full Text] [PDF]



Advertisement